Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.
CEO: Roger Bendelac. Company website
Drugs Made In America Acquisition II Corp. Right (DMIIR) trades at $0.09, up 33.05% on the day, as of Sep 20, 2026 14:58 UTC.
Drugs Made In America Acquisition II Corp. Right has a market capitalisation of $5.92M, calculated from the live DMIIR share price and shares outstanding.
DMIIR has no meaningful price-to-earnings ratio: Drugs Made In America Acquisition II Corp. Right lost $0.00 per share over the last twelve months, and a P/E is only defined on positive earnings.
Drugs Made In America Acquisition II Corp. Right generated revenue of $0.00 over the trailing twelve months.
DMIIR has traded between $0.06 and $0.13 over the past 52 weeks, and the last price is 28.5% below that high.
Yes. Drugs Made In America Acquisition II Corp. Right keeps 0.00% of revenue as net income over the trailing twelve months.
Drugs Made In America Acquisition II Corp. Right is classified under the Financial Services sector and the Asset Management industry, and is domiciled in US .
Roger Bendelac is the chief executive of Drugs Made In America Acquisition II Corp. Right.
QFI Terminal shows DMIIR with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open DMIIR in Terminal See plans